Know Cancer

or
forgot password

An Extension Study for Patients Previously Treated With ARQ 501


Phase 1/Phase 2
18 Years
N/A
Not Enrolling
Both
Cancer

Thank you

Trial Information

An Extension Study for Patients Previously Treated With ARQ 501


Inclusion Criteria:



- Signed written informed consent

- Has previous participated in a clinical trial with ARQ 501 and is eligible for
continued treatment

Exclusion Criteria:

- Have not received previous treatment with ARQ 501 under a treatment protocol

- Uncontrolled intercurrent illness, uncontrolled infection or psychiatric
illness/social situations that would limit compliance with study requirements

Type of Study:

Interventional

Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To provide ongoing treatment with ARQ 501 for patients who have benefited from prior treatment with ARQ 501

Outcome Time Frame:

No time frame

Safety Issue:

Yes

Principal Investigator

Neil Nathan Senzer, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mary Crowley Medical Research Center

Authority:

United States: Food and Drug Administration

Study ID:

ARQ 501-115

NCT ID:

NCT00622063

Start Date:

December 2006

Completion Date:

Related Keywords:

  • Cancer
  • cancer, solid tumor

Name

Location

Mary Crowley Medical Research CenterDallas, Texas  75246